CN112494504A - Application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine - Google Patents

Application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine Download PDF

Info

Publication number
CN112494504A
CN112494504A CN202011504037.XA CN202011504037A CN112494504A CN 112494504 A CN112494504 A CN 112494504A CN 202011504037 A CN202011504037 A CN 202011504037A CN 112494504 A CN112494504 A CN 112494504A
Authority
CN
China
Prior art keywords
galloyl
coronavirus
application
glucopyranose
tri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011504037.XA
Other languages
Chinese (zh)
Inventor
付军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Shengpu Life Technology Co ltd
Original Assignee
Guangdong Shengpu Life Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Shengpu Life Technology Co ltd filed Critical Guangdong Shengpu Life Technology Co ltd
Publication of CN112494504A publication Critical patent/CN112494504A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The application is a divisional application with the application number of 202011453321.9, the application date of 2020, 12 months and 11 days, and the invention name of the application is the application of gallic acid and derivatives and structural analogues thereof in preparing anti-coronavirus medicines. The invention belongs to the technical field of biological medicines, and particularly relates to application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparation of an anti-coronavirus medicine. The research of the invention shows that 1,2, 6-tri-O-galloyl-beta-D-glucopyranose has obvious antiviral effect on various viruses of Coronaviridae, including 2019 novel coronavirus (2019-nCoV or SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV) and the like. The substances have natural sources, are widely present in various plants, have wide application in the fields of food, biology and medicine, and are very safe, so the substances have good application value in the aspect of preparing and developing antiviral drugs aiming at the coronavirus family.

Description

Application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
The application is a divisional application with the application number of 202011453321.9, the application date of 2020, 12 months and 11 days, and the invention name of the application is the application of gallic acid and derivatives and structural analogues thereof in preparing anti-coronavirus medicines.
Technical Field
The invention belongs to the technical field of biological medicines. More particularly, relates to the application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicines.
Background
Coronaviruses belong to phylogenetic group of the order of the nested viruses (Nidovirales), the family of Coronaviridae (Coronaviridae), the genus coronaviruses (Coronavirus). Among them, viruses of the genus coronaviruses are enveloped (envelope) RNA viruses whose genome is a linear single-stranded positive strand, and are a large group of viruses widely existing in nature. The coronavirus has the diameter of about 80-120 nm, the 5 'end of the genome has a methylated cap structure, the 3' end has a poly (A) tail, and the total length of the genome is about 27-32 kb, so that the coronavirus is the largest virus in the genome of the currently known RNA viruses. Coronaviruses infect only vertebrates, including humans, and currently, coronaviruses known to infect humans and to bring about a very large epidemic situation are SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause diseases in the respiratory tract, digestive tract, liver, and nervous system. Human coronaviruses have been isolated in 1965, but until now their knowledge has been rather limited, and the serotype and antigenic variability of coronaviruses has not been clarified. Moreover, the coronavirus can be repeatedly infected, which shows that the coronavirus has a plurality of serotypes (at least 4 types are known) and antigenic variation, is difficult to immunize, and has no specific preventive and therapeutic medicine.
Only in experimental studies, it has been found that azauracil (α zauracil) and ribavirin (ribavirin, Virazole) and spiroadamantane (spiroadamantane) have significant inhibitory effects on coronavirus (Qian, Wang Rui. coronavirus infection characteristics and control [ J ] Chinesia Hospital J.Infectiong, 2003,013(011) (1097) -1100.).
However, the medicines are easy to cause adverse reactions such as diarrhea, anemia, dizziness, headache, weakness, hypodynamia and the like, and have certain potential safety hazards; moreover, with the variation of viruses and the appearance of new strains, the antiviral effect of the chemical drugs is greatly reduced, such as the new coronavirus 2019-nCoV appearing at the end of 2019, and until the drugs with exact curative effect are not found at present.
Disclosure of Invention
The invention aims to solve the technical problem of overcoming the defects and shortcomings of the existing coronavirus control technology and provides a new choice of anti-coronavirus medicines, namely gallic acid and derivatives and structural analogues thereof. The inventor discovers through a great deal of creative work that the seed acid, the derivatives and the structural analogs thereof have obvious anti-coronavirus effects, and the substances are widely present in various plants, have natural sources, are widely applied in the fields of food and biomedicine, and are very safe, so the preparation method has good application prospects in the aspects of preparing and developing antiviral drugs aiming at the coronavirus family.
The invention aims to provide application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicines.
It is another object of the present invention to provide a composition against viruses of the family Coronaviridae.
The invention also aims to provide the application of the composition for resisting the viruses of the family Coronaviridae in preparing anti-coronavirus medicaments.
The invention also aims to provide a medicament for resisting the coronavirus.
The above purpose of the invention is realized by the following technical scheme:
the research of the invention shows that the gallic acid and the derivatives and structural analogues thereof have obvious antiviral effect on the viruses of the family Coronaviridae.
Preferably, the coronavirus is a coronavirus genus virus.
Specifically, it has now been found that the identified viruses of the genus Coronaviridae include SARS-CoV, SARS-CoV-2 (or 2019-nCoV), MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU 1.
In addition, the invention verifies that dozens of reported gallic acid derivatives or gallic acid structural analogs have obvious antiviral effect on coronavirus viruses, the gallic acid derivatives or the gallic acid structural analogs have common galloyl and glycosyl, and experimental results prove that the compounds have good antiviral effect on the existing coronavirus. The mechanism of the correlation is further discussed.
We therefore believe that preferably the gallic acid derivatives are gallic acid derivatives containing galloyl groups and sugar groups and that the gallic acid and its derivatives and structural analogues contain galloyl groups and sugar groups.
Preferably, the gallic acid structural analog is a gallic acid structural analog containing galloyl and sugar groups.
Further, the galloyl is obtained by substituting a substitutable group on gallic acid; the glycosyl is obtained after the substitutable group on the six-carbon sugar is substituted.
Specifically, the gallic acid derivatives and structural analogs include the following (as shown in table 1):
ellagic acid, (-) -epigallocatechin gallate, 1,2,3,4, 6-O-pentagalloyl glucose, 1,2,3,4, 6-5-O-galloyl-beta-D-glucose, epicatechin gallate, quercetin 3-O- (6 "-galloyl) -beta-D-glucoside, kaempferol 3-O- (6" -galloyl) -beta-D-glucopyranoside, 2-O-cinnamoyl-1-O-galloyl-BETA-D-glucoside, 6-O-galloyl glucose, resveratrol-4' -O-BETA-D- (6 "-O-galloyl) glucoside, resveratrol-D, and its preparation method, 4' -hydroxyphenyl-2-butanone-4 ' -O-B-D- (2 ' -O-cinnamoyl-6 ' -O-galloyl glucoside, 4' -hydroxyphenyl-2-butanone-4 ' -O-B-D- (2-O-galloyl-6 ' -O-p-hydroxycinnamoyl) glucoside, 1,3, 6-tri-O-3, 4, 5-trihydroxybenzoyl-BETA-D-glucose, 1-galloylglucose, 1,4, 6-tri-O-galloyl-BETA-D-glucopyranose, resveratrol-4 ' -O- (6 ' -galloyl) glucopyranoside, BETA-glucosidase, BETA, 1,3,4, 6-tetra-O-galloyl-BETA-D-glucopyranose, quercetin 3-O- (6 "-galloyl) - β -D-galactoside, 3-O-galloyl- β -D-glucopyranose, 1, 4-di-O-galloyl- β -D-glucopyranose, 1,4, 6-tri-O-galloyl- β -D-glucopyranose, 1,2,3, 6-tetra-O-galloyl- β -D-glucopyranose, BETA, 1,2,4, 6-tetra-O-galloyl-beta-D-glucopyranose, 6-O-galloyl-D-glucopyranose, 3, 6-di-O-galloyl-D-glucopyranose, 3,4, 6-tri-O-galloyl-D-glucopyranose, 1,3, 4-tri-O-galloyl-6-O-caffeoyl-beta-D-glucopyranose, 1, 3-O-di-galloyl-6-O- (S) -caesalpinia-osa acyl-beta-D-glucopyranose, quercetin galloyl glucoside, galloyl paeoniflorin, galloyl glucose, 3,3' -O-dimethyl ellagic acid, 2,3, 8-tri-O-methyl ellagic acid, 3,4' -O-dimethyl ellagic acid, 4' -O-dimethyl ellagic acid, 3' -di-O-methyl-4-O- (BETA-D-xylopyranosyl) ellagic acid, epicatechin 3-O- (3-O-methyl) gallate, epigallocatechin 3-O- (3-O-methyl) gallate, 2 ' -O-galloylhyperoside, 5-galloylquinic acid, 3-galloylquinic acid, 4-galloylquinic acid, 3-O-galloylmucic acid, galloylquinic acid, galloylmucic acid, galloylquinic acid, galloylquini, 4-O-galloylbergenin.
TABLE 1 Gallic acid derivatives and detailed information
Figure BDA0002844344860000031
Figure BDA0002844344860000041
Figure BDA0002844344860000051
Figure BDA0002844344860000061
Figure BDA0002844344860000071
Figure BDA0002844344860000081
Figure BDA0002844344860000091
Figure BDA0002844344860000101
Figure BDA0002844344860000111
Figure BDA0002844344860000121
The invention is provided in table 1 as only one of the compounds, and the stereoisomers, geometric isomers, hydrates, solvates or pharmaceutically acceptable salts or prodrugs of the compounds in table 1 shall also fall within the scope of the invention.
The compounds and pharmaceutically acceptable salts of the present invention also include solvate or hydrate forms. In general, the solvate or hydrate forms are equivalent to the unsolvated or non-hydrated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in polymorphic or amorphous forms. In general, all physical forms are equally useful and contemplated as within the scope of the present invention.
"solvate" of the present invention refers to an association of one or more solvent molecules with a compound of the present invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. The term "hydrate" refers to an association of solvent molecules that is water.
The compounds of the invention exist in free form or, where appropriate, as pharmaceutically acceptable derivatives. According to the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of esters, or any other adduct or derivative that can be administered directly or indirectly in accordance with the needs of the patient, compounds described in other aspects of the invention, metabolites thereof, or residues thereof.
In the above pharmaceutical application of the invention, pharmaceutically acceptable adjuvants, carriers, excipients, diluents, vehicles and the like can be added to prepare different pharmaceutical dosage forms, such as injections, oral agents, sprays, inhalants and the like.
To prepare solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient (or carrier) to form a solid preformulation composition comprising a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect the tablets or pills against the action of the acidic conditions found in the stomach. For example, a tablet or pill may include an inner dose and an outer dose component, the latter having the form of a sheath over the former. The two components may be separated by an enteric layer which serves to prevent disintegration in the stomach and to allow the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials may be used for such enteric layers or coatings, including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutical excipients. Preferably, these compositions are administered by the oral or nasal respiratory route to obtain a local or systemic effect. Compositions in preferred pharmaceutically acceptable solvents may be nebulized by the use of inert gases. The nebulized solution may be inhaled directly from the nebulizing device, or the nebulizing device may be attached to a mask tent, or an intermittent positive pressure ventilator. The solution, suspension, or powder compositions may be administered from a device that delivers the dosage form in a suitable manner, preferably by the oral or nasal route.
Based on the above research results, the present invention further provides a composition against viruses of the family coronaviridae, comprising any two or more of gallic acid, gallic acid derivatives, and gallic acid structural analogs.
Further, the composition further comprises sialic acid.
The sialic acid source can be mammal mandible extract, nidus Collocaliae, breast milk, egg, cheese, etc. The mammal may be derived from cattle, pig, etc.
Preferably, the mass ratio of the gallic acid and the derivatives and structural analogues thereof to the sialic acid is 1 (0.01-20).
More preferably, the mass ratio of the galloyl and the derivatives and structural analogs thereof to the sialic acid is 1 (0.1-15).
The compound or the composition claimed by the invention is applied to preparing anti-coronavirus medicines, but is not limited to the application of using an effective amount of the compound or the pharmaceutical composition provided by the invention to prepare medicines for preventing or treating diseases caused by coronavirus, relieving the symptoms of the diseases caused by coronavirus or delaying the development or the onset of the diseases caused by coronavirus.
In addition to being beneficial for human therapy, the presently claimed compounds or compositions may also find application in veterinary therapy for pets, animals of the introduced species and animals in farms, including mammals, rodents, and the like. Other examples of animals include horses, dogs, cats, and the like.
The invention has the following beneficial effects:
the research result of the invention shows that 1,2, 6-tri-O-galloyl-beta-D-glucopyranose has obvious effect of resisting coronavirus, including SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1, and the invention is verified to have definite curative effect through live virus experiments and has wide application prospect in the field of preparing anti-coronavirus medicines.
Furthermore, the 1,2, 6-tri-O-galloyl-beta-D-glucopyranose and sialic acid form a composition, the effect of resisting coronavirus is obviously improved, and the composition has obvious synergistic effect.
In addition, the 1,2, 6-tri-O-galloyl-beta-D-glucopyranose or sialic acid is natural in source, widely exists in various animals and plants, is a natural active compound existing in the nature, has wide application in the fields of food, biology and medicine, is very safe, and has good medicine development foundation.
Detailed Description
The present invention is further illustrated by the following specific examples, which are not intended to limit the invention in any way. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated. Unless otherwise indicated, reagents and materials used in the following examples are commercially available.
The active virus experiments of the invention are all entrusted to the Guangdong province disease control center, and the microbial materials are provided by the Guangdong province disease control center.
EXAMPLE 1 half-infected cell number (TCID)50) Measurement of (2)
1. Experimental Material
Virus: 2019-nCoV; cell lines: human embryonic kidney cells 293(HEK293 cells); DMEM medium; 96-well culture plates.
2. Experimental procedure
(1) The virus was serially diluted 10-fold in DMEM medium in a centrifuge tube from 10-1To 10-6Incubating for 1-2 hours on ice;
(2) adding virus solutions with different concentrations into a 96-well culture plate, inoculating one longitudinal row of 8 wells in total for each dilution, inoculating 100 mu l of virus solution into each well, and adding DMEM culture medium without virus into the two rows to serve as normal control;
(3) digesting, suspending and counting cultured human embryonic kidney cells 293(HEK293 cells), adding 100 mu l of cell suspension into each well of a 96-well plate containing viruses to ensure that the cell density is 2-3 multiplied by 105Per mL;
(4)37℃、5％CO2culturing in an incubator, observing cytopathic effect (CPE) until the lowest dilution is no longer diseased (generally, observing for 5-7 days), observing the cytopathic effect (CPE) under an inverted microscope, and recording cytopathic effect;
(5) calculating the half-infection amount (TCID) of the cells by a Reed-Muench method50)。
3. Results of the experiment
According to the cytopathic condition caused by virus infection HEK293 cells, the TCID is calculated by a Reed-Muench method50＝10－4.7/0.1mL。
Example 2 Effect on the Activity of 2019-nCoV Virus to infect HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is 2019-nCoV; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. Experimental procedure
(1) Taking cell culture fluid, and diluting the medicine into series of mass concentrations (100, 33.33, 11.11, 3.70, 1.23, 0.41 and 0.00 mg/mL);
(2) get 50TCID again50The 2019-nCoV virus solution and the medicine solution are neutralized in equal volume;
(3) incubating at 37 deg.C for 1h, inoculating into HEK293 cell at 100 μ L/well with each mass concentration of 4 multiple wells, simultaneously setting normal cell control group, virus control group and positive control group, incubating at 37 deg.C with 5% CO2Culturing and observing cell morphology;
(4) after 48h, the OD was measured by a microplate reader using MTT method490Value, calculationHalf Effective Concentration (EC) of drug50)。
3. The experimental results are as follows:
as shown in Table 2, compounds 1-45 all showed higher antiviral activity, with EC50The value range is 3 to 20. mu.g/ml.
TABLE 2 EC of compounds on 2019-nCoV infected human embryonic kidney cell 293(HEK293 cell) line50Value of
Figure BDA0002844344860000161
Example 3 Effect on the Activity of SARS-CoV Virus infecting HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is SARS-CoV; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in Table 3, compounds 1-45 all showed higher antiviral activity, with EC50The value range is 3 to 18. mu.g/ml.
TABLE 3 EC of Compounds on SARS-CoV Virus-infected human embryonic Kidney cell 293(HEK293 cells) line50Value of
Figure BDA0002844344860000171
Figure BDA0002844344860000181
Example 4 Effect on the Activity of MERS-CoV Virus to infect HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is MERS-CoV; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in Table 4, compounds 1-45 all showed higher antiviral activity, with EC50The value range is 3 to 18. mu.g/ml.
TABLE 4 EC of Compounds on MERS-CoV infected human embryonic Kidney cell 293(HEK 293) line50Value of
Figure BDA0002844344860000182
Figure BDA0002844344860000191
EXAMPLE 5 Effect on HCoV-229E Virus Activity to infect HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is HCoV-229E; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in Table 5, compounds 1-45 all exhibited higher antiviral activity, with their EC50The value range is 3 to 17. mu.g/ml.
TABLE 5 EC of Compounds on HCoV-229E infected human embryonic Kidney cell 293(HEK 293) line50Value of
Figure BDA0002844344860000192
Figure BDA0002844344860000201
Example 6 Effect on the Activity of HCoV-NL63 Virus on infection of HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is HCoV-NL 63; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in Table 6, compounds 1-45 all exhibited higher antiviral activity, with their EC50The value range is 3 to 16 mu g/ml.
TABLE 6 EC of Compounds on HCoV-NL63 Virus infected human embryonic Kidney cell 293(HEK293 cell) line50Value of
Figure BDA0002844344860000202
Figure BDA0002844344860000211
Example 7 Effect on HCoV-OC43 Virus Activity in infecting HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is HCoV-OC 43; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in Table 7, compounds 1-45 all exhibited higher antiviral activity, with their EC50The value range is 3 to 18. mu.g/ml.
TABLE 7 EC of compounds on HCoV-OC43 virus-infected human embryonic kidney cell 293(HEK293 cell) line50Value of
Figure BDA0002844344860000221
Example 8 Effect on HCoV-HKU1 Virus Activity to infect HEK293 cells
1. Experimental materials:
(1) medicine preparation: sialic acid and the compound of table 1.
(2) Other test materials
The virus is HCoV-HKU 1; the cell line is human embryonic kidney cell 293(HEK293 cell); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in Table 8, compounds 1-45 all exhibited higher antiviral activity, with their EC50The value range is 3 to 17. mu.g/ml.
TABLE 8 EC of compounds on HCoV-HKU1 virus-infected human embryonic kidney cell 293(HEK293 cells) line50Value of
Figure BDA0002844344860000231
Figure BDA0002844344860000241
Example 9 Effect of sialic acid combinations on the Activity of coronavirus infection of HEK293 cells
1. Experimental materials:
(1) medicine preparation: compounds 1,3,4, 5, 14, 17, 18, 22, 23, 24, 25, 28, 29, 30, 39, 40 in table 1; sialic acid (CAS: 131-48-6), compound to sialic acid ratio was 1: 10.
(2) Other test materials
Virus: SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU 1; cell lines: human embryonic kidney cells 293(HEK293 cells); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows: reference is made to example 2.
3. The experimental results are as follows:
as shown in tables 9-15, the combination of the compound and sialic acid shows higher antiviral activity, and shows obvious synergistic effect, and the EC of the compound and sialic acid shows50The value range is 2 to 10 mu g/ml.
TABLE 9 EC of compositions on SARS-CoV coronavirus infected human embryonic kidney cell 293(HEK293 cells) lines50Value of
Figure BDA0002844344860000242
Figure BDA0002844344860000251
TABLE 10 EC of compositions on SARS-CoV-2 coronavirus infected human embryonic kidney cell 293(HEK293 cells) line50Value of
Figure BDA0002844344860000252
TABLE 11 EC of compositions on MERS-CoV coronavirus infected human embryonic kidney 293(HEK 293) cell line50Value of
Figure BDA0002844344860000253
TABLE 12 EC of compositions on HCoV-229E coronavirus infected human embryonic kidney cell 293(HEK293 cells) line50Value of
Figure BDA0002844344860000254
Figure BDA0002844344860000261
TABLE 13 EC of compositions on HCoV-NL63 coronavirus infected human embryonic kidney cell 293(HEK293 cell) line50Value of
Figure BDA0002844344860000262
TABLE 14 EC of compositions on HCoV-OC43 coronavirus infected human embryonic kidney cell 293(HEK293 cells) line50Value of
Figure BDA0002844344860000263
Figure BDA0002844344860000271
TABLE 15 EC of compositions on HCoV-HKU1 coronavirus infected human embryonic kidney cell 293(HEK293 cells) line50Value of
Figure BDA0002844344860000272
EXAMPLE 10 synergistic Effect study with sialic acid compositions against coronavirus infection
1. Experimental materials:
(1) medicine preparation: compound 23 in table 1; sialic acid (CAS: 131-48-6), compound to sialic acid ratio was 1: 10.
(2) Other test materials
Virus: SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU 1; cell lines: human embryonic kidney cells 293(HEK293 cells); DMEM medium; 96-well culture plates.
2. The experimental steps are as follows:
diluting the medicine into a series of preparations by taking cell culture solutionMass concentration; get 50TCID again50The virus solution is respectively neutralized with the medicine solution in the same volume; incubating at 37 deg.C for 1h, inoculating into HEK293 cell at 100 μ L/well with each mass concentration of 4 multiple wells, simultaneously setting normal cell control group, virus control group and drug adding group, incubating at 37 deg.C with 5% CO2Culturing and observing cell morphology; after 48h, the OD was measured by a microplate reader using MTT method490Values, simultaneous calculation of cell viability and gold positive mean q-values (q)<0.85 is antagonistic, q is more than or equal to 0.85<1.15 is additive effect, q is more than or equal to 1.15 is synergistic effect).
3. The experimental results are as follows: see tables 16-22.
As can be seen from tables 16-22, the compound 23 of the present invention has a q value of not less than 1.15 for each virus when used in combination with sialic acid, and has an obvious synergistic effect.
TABLE 16 Effect of Compounds and sialic acid against SARS-CoV coronavirus
Figure BDA0002844344860000281
TABLE 17 Effect of Compounds and sialic acid against SARS-CoV-2 coronavirus
Figure BDA0002844344860000282
TABLE 18 Compound and sialic acid anti-MERS-CoV coronavirus Effect
Figure BDA0002844344860000283
Figure BDA0002844344860000291
TABLE 19 Compound and sialic acid anti-HCoV-229E Virus Effect
Figure BDA0002844344860000292
TABLE 20 Compounds and sialic acid anti-HCoV-NL 63 Virus Effect
Figure BDA0002844344860000293
TABLE 21 Compounds and sialic acid anti-HCoV-OC 43 Virus Effect
Figure BDA0002844344860000301
TABLE 22 Compound and sialic acid anti-HCoV-HKU Virus Effect
Figure BDA0002844344860000302
In addition, the invention also examines the dosage ratio of the compound 23 and the sialic acid, and the result shows that the mass ratio of the compound 23 and the sialic acid is controlled to be better within the range of 1 (0.01-20) (more preferably 1 (0.1-15), and most preferably 1:10), so that the invention can play a remarkable synergistic effect and reduce the dosage.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (10)

  1. The application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicines is characterized in that the 1,2, 6-tri-O-galloyl-beta-D-glucopyranose has the following structural formula:
    Figure FDA0002844344850000011
  2. 2. the use of claim 1, wherein the virus is a coronavirus.
  3. 3. The use of claim 2, wherein the coronaviruses are SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 or HCoV-HKU 1.
  4. 4. A composition against a virus of the family coronaviridae, said composition comprising 1,2, 6-tri-O-galloyl- β -D-glucopyranose and sialic acid.
  5. 5. The composition of claim 4, wherein the mass ratio of 1,2, 6-tri-O-galloyl- β -D-glucopyranose to sialic acid is 1 (0.01-20).
  6. 6. The composition according to claim 5, wherein the mass ratio of 1,2, 6-tri-O-galloyl- β -D-glucopyranose to sialic acid is 1: (0.1-15).
  7. 7. The composition of claim 6, wherein the mass ratio of 1,2, 6-tri-O-galloyl- β -D-glucopyranose to sialic acid is 1: 10.
  8. 8. Use of a composition according to any one of claims 4 to 7 for the manufacture of a medicament against a virus of the family Coronaviridae.
  9. 9. The use of claim 8, wherein the pharmaceutical dosage form is an injection, an oral agent, a spray, or an inhalant.
  10. 10. A medicament against a virus of Coronaviridae, comprising 1,2, 6-tri-O-galloyl- β -D-glucopyranose or a composition according to any one of claims 4 to 7.
CN202011504037.XA 2020-06-11 2020-12-11 Application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine Pending CN112494504A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010530974.6A CN111658631A (en) 2020-06-11 2020-06-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine
CN2020105309746 2020-06-11
CN202011453321.9A CN112336709A (en) 2020-06-11 2020-12-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202011453321.9A Division CN112336709A (en) 2020-06-11 2020-12-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine

Publications (1)

Publication Number Publication Date
CN112494504A true CN112494504A (en) 2021-03-16

Family

ID=72386666

Family Applications (18)

Application Number Title Priority Date Filing Date
CN202010530974.6A Pending CN111658631A (en) 2020-06-11 2020-06-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine
CN202011504040.1A Pending CN112546054A (en) 2020-06-11 2020-12-11 Application of galloyl-BETA-D-glucopyranose in preparing anti-coronavirus medicine
CN202011504016.8A Pending CN112546053A (en) 2020-06-11 2020-12-11 Application of tri-galloyl-caffeoyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN202011509383.7A Pending CN112843079A (en) 2020-06-11 2020-12-11 Application of galloyl caesalpinia caesalpina acyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN202011509438.4A Pending CN112472691A (en) 2020-06-11 2020-12-11 Anti-coronavirus gallic acid composition and application thereof
CN202011504038.4A Pending CN112587536A (en) 2020-06-11 2020-12-11 Application of resveratrol-4 '-O- (6' -galloyl) glucopyranoside in preparing anti-coronavirus medicine
CN202011509369.7A Pending CN112569244A (en) 2020-06-11 2020-12-11 Application of 3,4, 6-tri-O-galloyl-D-glucopyranose in preparing anti-coronavirus medicine
CN202011509388.XA Pending CN112451535A (en) 2020-06-11 2020-12-11 Application of 1,4, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN202011504037.XA Pending CN112494504A (en) 2020-06-11 2020-12-11 Application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN202011504018.7A Pending CN112494503A (en) 2020-06-11 2020-12-11 Application of 1,2,4, 6-tetra-O-galloyl-beta-D-glucopyranose in preparing anti-coronary virus medicine
CN202011504069.XA Pending CN112546055A (en) 2020-06-11 2020-12-11 Application of 1,2,3,4, 6-5-O-galloyl-beta-D-glucose in preparation of anti-coronavirus drugs
CN202011509415.3A Pending CN112472706A (en) 2020-06-11 2020-12-11 Application of 1,2,3,4, 6-O-pentagalloyl glucose in preparation of anti-coronavirus medicines
CN202011504039.9A Pending CN112587537A (en) 2020-06-11 2020-12-11 Application of trihydroxy benzoyl-BETA-D-glucose in preparing anti-coronavirus medicine
CN202011504108.6A Pending CN112546041A (en) 2020-06-11 2020-12-11 Application of (-) -epigallocatechin gallate in preparing anti-coronavirus medicine
CN202011504014.9A Pending CN112451517A (en) 2020-06-11 2020-12-11 Application of epigallocatechin 3-O- (3-O-methyl) gallate in preparing anti-coronavirus medicine
CN202011509374.8A Pending CN112843074A (en) 2020-06-11 2020-12-11 Application of 1,2,3, 6-tetra-O-galloyl-beta-D-glucopyranose in preparing anti-coronary virus medicine
CN202011504011.5A Pending CN112587540A (en) 2020-06-11 2020-12-11 Application of 2' -O-galloyl hyperin in preparing anti-coronavirus medicine
CN202011453321.9A Pending CN112336709A (en) 2020-06-11 2020-12-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine

Family Applications Before (8)

Application Number Title Priority Date Filing Date
CN202010530974.6A Pending CN111658631A (en) 2020-06-11 2020-06-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine
CN202011504040.1A Pending CN112546054A (en) 2020-06-11 2020-12-11 Application of galloyl-BETA-D-glucopyranose in preparing anti-coronavirus medicine
CN202011504016.8A Pending CN112546053A (en) 2020-06-11 2020-12-11 Application of tri-galloyl-caffeoyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN202011509383.7A Pending CN112843079A (en) 2020-06-11 2020-12-11 Application of galloyl caesalpinia caesalpina acyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN202011509438.4A Pending CN112472691A (en) 2020-06-11 2020-12-11 Anti-coronavirus gallic acid composition and application thereof
CN202011504038.4A Pending CN112587536A (en) 2020-06-11 2020-12-11 Application of resveratrol-4 '-O- (6' -galloyl) glucopyranoside in preparing anti-coronavirus medicine
CN202011509369.7A Pending CN112569244A (en) 2020-06-11 2020-12-11 Application of 3,4, 6-tri-O-galloyl-D-glucopyranose in preparing anti-coronavirus medicine
CN202011509388.XA Pending CN112451535A (en) 2020-06-11 2020-12-11 Application of 1,4, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine

Family Applications After (9)

Application Number Title Priority Date Filing Date
CN202011504018.7A Pending CN112494503A (en) 2020-06-11 2020-12-11 Application of 1,2,4, 6-tetra-O-galloyl-beta-D-glucopyranose in preparing anti-coronary virus medicine
CN202011504069.XA Pending CN112546055A (en) 2020-06-11 2020-12-11 Application of 1,2,3,4, 6-5-O-galloyl-beta-D-glucose in preparation of anti-coronavirus drugs
CN202011509415.3A Pending CN112472706A (en) 2020-06-11 2020-12-11 Application of 1,2,3,4, 6-O-pentagalloyl glucose in preparation of anti-coronavirus medicines
CN202011504039.9A Pending CN112587537A (en) 2020-06-11 2020-12-11 Application of trihydroxy benzoyl-BETA-D-glucose in preparing anti-coronavirus medicine
CN202011504108.6A Pending CN112546041A (en) 2020-06-11 2020-12-11 Application of (-) -epigallocatechin gallate in preparing anti-coronavirus medicine
CN202011504014.9A Pending CN112451517A (en) 2020-06-11 2020-12-11 Application of epigallocatechin 3-O- (3-O-methyl) gallate in preparing anti-coronavirus medicine
CN202011509374.8A Pending CN112843074A (en) 2020-06-11 2020-12-11 Application of 1,2,3, 6-tetra-O-galloyl-beta-D-glucopyranose in preparing anti-coronary virus medicine
CN202011504011.5A Pending CN112587540A (en) 2020-06-11 2020-12-11 Application of 2' -O-galloyl hyperin in preparing anti-coronavirus medicine
CN202011453321.9A Pending CN112336709A (en) 2020-06-11 2020-12-11 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine

Country Status (1)

Country Link
CN (18) CN111658631A (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461057A (en) 2020-04-01 2022-12-09 生命科学股份有限公司 Sialic acid compositions for inhibiting and treating coronavirus infection
US20210236580A1 (en) * 2020-04-07 2021-08-05 Sytheon Ltd Methods and Compositions for Mitigating Symptoms of Acute Respiratory Distress Syndrome
CN111658631A (en) * 2020-06-11 2020-09-15 广东盛普生命科技有限公司 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine
WO2022029334A1 (en) * 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
CN112220808A (en) * 2020-11-18 2021-01-15 上海中医药大学 Ephedra extract and active component and application thereof
CN112521432B (en) * 2020-11-25 2022-05-06 深圳市三启药物开发有限公司 Star-shaped spine protein targeted bifunctional compound for resisting respiratory tract infection virus and preparation method and application of salts thereof
EP4011367A1 (en) * 2020-12-09 2022-06-15 Dompe' Farmaceutici S.P.A. Compounds for use in the treatment of covid-19
TR202020545A2 (en) * 2020-12-15 2021-01-21 Cukurova Ueniversitesi Rektoerluegue EFFECTIVE AGENT IN THE TREATMENT OF COVID-19 / SARS-CoV-2
CN112891336A (en) * 2021-02-01 2021-06-04 南湖实验室 Medical application of gallocatechin gallate and derivatives thereof
CN113143902A (en) * 2021-03-30 2021-07-23 深圳湾实验室 Use of gallic acid and/or chlorogenic acid for treating coronavirus infection
CN113429372B (en) * 2021-06-21 2023-10-13 安徽农业大学 Novel 3C-like protease inhibitor and preparation method and application thereof
WO2023026867A1 (en) * 2021-08-24 2023-03-02 株式会社Hpg Aqueous catechin-containing solution composition having excellent storage stability, and use thereof
CN113712984B (en) * 2021-09-29 2024-01-12 中国药科大学 Application of PNPT 1-based small molecule inhibitor combination in preparation of antiviral drugs
CN113995748B (en) * 2021-11-17 2023-05-02 武汉轻工大学 Application of ellagic acid in preparation of medicines or feed additives for treating or preventing porcine viral diarrhea
CN114831978A (en) * 2022-04-26 2022-08-02 江汉大学 Application of resveratrol triphenol c in preparing anti-SARS-CoV-2 infection medicine
CN116077560A (en) * 2023-01-31 2023-05-09 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) Application of EGCG composition in preparation of medicines for treating novel coronaviruses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602853A (en) * 2003-10-20 2005-04-06 北京大学 Active constituent of traditional Chinese medicine capable of inhibiting SARS coronavirus infection and its bioactivity measuring method
WO2005056047A1 (en) * 2003-10-09 2005-06-23 United States Army Medical Research And Materiel Command Use of sialic acid, analogues of sialic acid, and antibodies to sialidases as anti-infectious agents and anti-inflammatory agents
KR20120118707A (en) * 2011-04-19 2012-10-29 원광대학교산학협력단 A composition comprising the extract of galla rhois or the compounds isolated therefrom showing inhibiting activity of novel influenza, avian influenza, or sars syndrome
WO2016169573A1 (en) * 2015-04-20 2016-10-27 Elsebai Mahmoud Fahmi Sesquiterpene lactones as potent and broad spectrum antiviral compounds against all genotypes of hepatitis c virus (hcv)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1048489C (en) * 1993-10-30 2000-01-19 山东省医学科学院药物研究所 Novel anti-virus compound methyl brevifolin carboxylic ester and method for prepn. of same
JPH07149785A (en) * 1993-11-26 1995-06-13 Showa Shell Sekiyu Kk Gallic acid derivative and antiviral agent containing the derivative as active component
KR100408231B1 (en) * 2000-08-14 2003-12-01 한국 한의학 연구원 Flavonoid derivateives for prevention and treatment of osteoporosis
DE60118592T2 (en) * 2000-10-06 2007-05-16 Phytrix Inc. PHYLLANTHUS COMPOUNDS FOR THE PREVENTION AND / OR TREATMENT OF DISEASES RELATED TO A RETROVIRUS
CN1695627A (en) * 2004-05-12 2005-11-16 四川省中药研究所 Medicine for anti hepatitis B
CN1795850A (en) * 2004-12-22 2006-07-05 财团法人台湾血液净化基金会 Composition for preventing or curing SARS, and health food of containing the composition
CN1830449A (en) * 2005-03-11 2006-09-13 中国科学院上海药物研究所 Medical use of flavine-3-beta galactoside and its preparation
JPWO2006100710A1 (en) * 2005-03-18 2008-08-28 太陽化学株式会社 Composition for prevention and treatment of severe acute respiratory syndrome
CN1990479A (en) * 2005-12-29 2007-07-04 中国科学院上海药物研究所 3-alkoxy substituted-2, 5, 7-tri-substituted benzopyran-4-ketones compounds, preparing method thereof and pharmaceutical compounds containing same
EP1867729A1 (en) * 2006-06-14 2007-12-19 Libragen Water soluble phenolics derivatives with dermocosmetic and therapeutic applications
CN101121738B (en) * 2007-09-06 2010-05-19 南方医科大学 1,3-O-di-galloyl-6-O-(S)-decapetalous caesalpinia acyl-beta-D-glucopyranose and application thereof
CN101152193B (en) * 2007-09-28 2010-07-21 南方医科大学 Application of 1,3,4-3-O-gallnut acyl-6-O-coffee acyl-beta-D-glucopyranose in preparing antineoplastic medicament
GB0801032D0 (en) * 2008-01-21 2008-02-27 Univ York Immune modulation
FR2934998B1 (en) * 2008-08-12 2010-09-03 Robert Vachy NOVEL GLUCOPYRANOSE DERIVATIVES, THEIR PREPARATION AND BIOLOGICAL APPLICATIONS
CN102349943A (en) * 2008-10-09 2012-02-15 丹东药业集团有限公司 Juglans mandshurica husk extractive and preparation method thereof
CN101744829A (en) * 2008-12-12 2010-06-23 凌沛学 Application of hyperin for treating herpes zoster, burn, scald, traumatic infection and tumors
TWI415572B (en) * 2011-06-17 2013-11-21 Univ Chang Gung Inhibition of biofilm formation by 1,2,3,4,6-penta-o-galloyl-d-glucopyranose
CN103156830A (en) * 2011-12-13 2013-06-19 天津市国际生物医药联合研究院 Application of aloe-emodin in resisting SARS coronavirus infection
RU2015104535A (en) * 2012-07-11 2016-08-27 Стемтек Интернэшнл, Инк. COMPOSITIONS AND METHODS FOR STRENGTHENING MOBILIZATION AND PROLIFERATION OF BLASTOMERO-LIKE STEM CELLS
WO2014090832A1 (en) * 2012-12-11 2014-06-19 Sandoz Ag Tannin derivative and pharmaceutical compositions comprising said tannin derivative
WO2015082950A1 (en) * 2013-12-02 2015-06-11 Sirbal Ltd. Herbal combinations for treatment of a skin condition
CN108451959B (en) * 2015-06-10 2021-04-20 苏州禾研生物技术有限公司 Application of galloylglucoside derivatives and pharmaceutical composition for treating hyperuricemia
US10195241B2 (en) * 2015-06-26 2019-02-05 Emory University Botanical extracts and compounds from Castanea plants and methods of use
CN105535012B (en) * 2016-01-27 2018-03-13 中国人民解放军疾病预防控制所 A kind of broad spectrum activity inhibitors of viral infection
CN105687226B (en) * 2016-01-27 2018-04-13 中国人民解放军疾病预防控制所 A kind of preparation for being used to suppress coronavirus infection
CN105669790B (en) * 2016-03-08 2016-09-21 中南林业科技大学 A kind of Bibenzyl compound and extracting method thereof
CN105859803B (en) * 2016-05-09 2018-10-26 中国农业科学院特产研究所 A kind of preparation method of galloyl glucose
CN110913857A (en) * 2017-04-20 2020-03-24 港大科桥有限公司 Zika virus protease inhibitors and methods of use thereof
CN107474083B (en) * 2017-07-13 2020-04-24 中国科学院西北高原生物研究所 Novel preparation method of stilbene and phenylbutanone chemical reference substance in rhubarb medicinal material
KR102234745B1 (en) * 2018-01-31 2021-04-01 국민대학교 산학협력단 Compounds that inhibit MERS coronavirus helicase nsP13 and uses thereof
CN111658631A (en) * 2020-06-11 2020-09-15 广东盛普生命科技有限公司 Application of gallic acid and its derivatives and structural analogs in preparing anti-coronavirus medicine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056047A1 (en) * 2003-10-09 2005-06-23 United States Army Medical Research And Materiel Command Use of sialic acid, analogues of sialic acid, and antibodies to sialidases as anti-infectious agents and anti-inflammatory agents
CN1602853A (en) * 2003-10-20 2005-04-06 北京大学 Active constituent of traditional Chinese medicine capable of inhibiting SARS coronavirus infection and its bioactivity measuring method
KR20120118707A (en) * 2011-04-19 2012-10-29 원광대학교산학협력단 A composition comprising the extract of galla rhois or the compounds isolated therefrom showing inhibiting activity of novel influenza, avian influenza, or sars syndrome
WO2016169573A1 (en) * 2015-04-20 2016-10-27 Elsebai Mahmoud Fahmi Sesquiterpene lactones as potent and broad spectrum antiviral compounds against all genotypes of hepatitis c virus (hcv)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘妍如等: "基于TCMSP数据库中药成分的新型冠状病毒3CL水解酶抑制剂虚拟筛选", 《中草药》 *
孙魏 等: "三没食子酰吡喃葡糖作用于gp41 抑制HIV 与靶细胞的融合", 《南方医科大学学报》 *

Also Published As

Publication number Publication date
CN112472706A (en) 2021-03-12
CN112569244A (en) 2021-03-30
CN112546053A (en) 2021-03-26
CN112451535A (en) 2021-03-09
CN112587537A (en) 2021-04-02
CN111658631A (en) 2020-09-15
CN112472691A (en) 2021-03-12
CN112546041A (en) 2021-03-26
CN112451517A (en) 2021-03-09
CN112587536A (en) 2021-04-02
CN112494503A (en) 2021-03-16
CN112587540A (en) 2021-04-02
CN112336709A (en) 2021-02-09
CN112546054A (en) 2021-03-26
CN112843074A (en) 2021-05-28
CN112546055A (en) 2021-03-26
CN112843079A (en) 2021-05-28

Similar Documents

Publication Publication Date Title
CN112494504A (en) Application of 1,2, 6-tri-O-galloyl-beta-D-glucopyranose in preparing anti-coronavirus medicine
CN111759851B (en) Application of tannic acid in preparing anti-coronavirus medicine
CN102188422A (en) Compound florfenicol injection and preparation method and application thereof
CN113244212A (en) Application of baicalein in preparation of medicine for preventing and/or treating novel coronavirus infection diseases
CN112245424B (en) Application of bisabolane sesquiterpene structural analogue in preparation of anti-coronavirus medicines
CN105456281B (en) A kind of veterinary medical composition and its production and use
CN115192556B (en) Application of isoliquiritigenin in preparation of medicines for resisting porcine epidemic diarrhea virus
CN117679362B (en) Veterinary valnemulin solution and preparation method and application thereof
CN115813912B (en) Application of sea ennone in preparation of medicine for preventing and treating African swine fever
CN113304158B (en) Application of sulfamethoxypyrazine in preparation of product for preventing and/or treating bovine parainfluenza virus
CN111067898B (en) Application of berberine hydrochloride in resisting carp herpesvirus II in aquaculture
CN105497001A (en) Use of resveratrol polymer in prevention and treatment of myelosuppression
CN105560218A (en) Use of resveratrol homologues in prevention and treatment on myelosuppression
CN114641285A (en) Formulations comprising plant extracts
CN106474126B (en) Application of anticancer small molecule compound sorafenib in treating liver echinococcosis
CN111297889A (en) A composition for inhibiting gastrointestinal spasm and biliary system spasm, its aqueous solution and its preparation method
CN117679362A (en) Veterinary valnemulin solution and preparation method and application thereof
CN117562890A (en) Application of chromone compound in preparation of anti-coronavirus drugs
CN111643529A (en) Application of crocodile blood in preparing anti-tumor and anti-virus medicines
CN114617885A (en) Application of isoliensinine in preparation of drugs for treating solid tumors
CN113398120A (en) Application of Abidol in preparing medicine for preventing or treating SARS-CoV-2 virus disease
CN113440562A (en) Application of compound houttuynia cordata mixture in preparation of medicine for preventing or treating coronavirus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210316